Peptide Trainings

TB-500

TB-500 is an acetylated seven-amino-acid fragment of thymosin beta-4 studied in laboratory models. Human safety and benefit are not established.

This material is educational, not medical advice or a treatment recommendation. Classroom claims and example protocols have not all been independently verified.

Source correction: The Skool course labeled TB-500 currently describes thymosin alpha-1. Those are different peptides. This profile instead uses FDA and peer-reviewed TB-500 sources; the Skool TB-500 lessons still need correction.

The Compound, Explained

TB-500 is a synthetic, N-terminally acetylated seven-amino-acid peptide with the sequence Ac-LKKTETQ. It corresponds to amino acids 17 through 23 of thymosin beta-4, a naturally occurring peptide with 43 amino acids.

The names are easy to mix up. TB-500 is not full-length thymosin beta-4, and neither is thymosin alpha-1. Alpha-1 is a different molecule with a different research history. A study of one should not be presented as proof about another.

Researchers study TB-500 in relation to actin dynamics and tissue-repair biology. It is not an FDA-approved drug. A 2026 FDA advisory committee recommendation about possible compounding-list inclusion was non-binding and did not establish safety, effectiveness, or drug approval.

Inside the Mechanism

The LKKTET segment sits in the actin-binding region of full-length thymosin beta-4. Actin helps cells maintain shape and move. Scientists have proposed that the related TB-500 fragment could affect these pathways, but sharing a sequence does not prove identical biological activity.

One especially important distinction is acetylation: TB-500 has an acetyl group at its N-terminus, while some older animal experiments used the non-acetylated LKKTETQ fragment. FDA cautions that results for the non-acetylated fragment cannot automatically be carried over to TB-500.

In a 2024 laboratory scratch assay, intact TB-500 did not significantly increase fibroblast wound closure under the conditions studied. One smaller metabolite, Ac-LKKTE, did show an effect in that cell assay. That finding suggests a question for further research, not a demonstrated healing effect in people.

What the Research Actually Shows

As of the FDA 2026 review, the agency had not identified human clinical studies or human exposure data for TB-500 free base or acetate. It also had not identified in-vivo studies demonstrating wound healing for those exact substances. Studies of full-length thymosin beta-4 or an unacetylated fragment answer different questions.

The research on intact TB-500 itself is mainly analytical and laboratory based. Its effects, clinical safety, and potential risks in humans remain unknown. No practical-use regimen follows from this evidence.

Selected sources

FDA: TB-500 briefing document for the July 2026 advisory meeting

Rahaman et al., 2024: TB-500 metabolites and a fibroblast assay (PubMed)

Esposito et al., 2012: analytical identification of Ac-LKKTETQ

Sourcing & Verification

A product called TB-500 should specify which molecule is being tested. The acetylated heptapeptide Ac-LKKTETQ is not full-length 43-amino-acid thymosin beta-4 and is not thymosin alpha-1. A report for one cannot silently stand in for another.

The Skool TB-500 course currently contains thymosin alpha-1 text. No COA file was attached to that course. We will not present its source material or a different product report as a valid TB-500 certificate.

A COA describes the tested sample and methods. It does not establish sterility, safety, clinical outcomes, or the contents of unrelated lots.

Preparation

There is no validated human preparation standard for TB-500 from the research reviewed here. The original Skool lesson in this position describes thymosin alpha-1 and is therefore not reproduced as TB-500 guidance.

For lab research literacy, separate a reagent identity claim from evidence on the stability and handling of the exact formulated material. A label alone cannot establish either.

Measurement

Before interpreting any measurement, verify that the document tests Ac-LKKTETQ rather than full-length thymosin beta-4 or thymosin alpha-1. Mass consistency is not, by itself, proof of full sequence or purity.

FDA found no clinical studies defining human exposure, pharmacokinetics, or pharmacodynamics for TB-500. No human-use measurement instructions can be inferred from that gap.

Protocol

FDA did not identify human clinical studies or an established TB-500 regimen in its 2026 review. The Skool lesson labeled TB-500 Protocol actually discusses thymosin alpha-1, a different compound, so it is not copied as a TB-500 protocol.

The button above opens a related Wolverine Stack lesson, which discusses TB-500 as one component; it is not a standalone, clinically validated TB-500 protocol.

Stack Logic

TB-500 is frequently discussed alongside BPC-157. Studies on one component do not prove that the combination works or is safe. The two-compound mixture has its own evidence gap.

The related Wolverine Stack course is linked as a primary source for what the classroom teaches, not as proof of human benefit. Check exact molecules, study design, and outcomes before drawing conclusions.

Certificate of Analysis

No COA attachment was available for this course when checked.

All classroom topics